TrialJournal of the American Heart Association2022

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.

Jing-Wei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.